PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. - Wikidata - wikimedia - TriplyDB

PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.

PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.

http://www.wikidata.org/entity/Q34644359

about

Telomere and Telomerase Therapeutics in Cancer Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer Viro-immune therapy: A new strategy for treatment of pancreatic cancer Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors Targeting tumor-associated macrophages to combat pancreatic cancer Immune checkpoint therapy for pancreatic cancer Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations.Does vaccine-primed pancreatic cancer offer better candidates for immune-based therapies?Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.T Cell Vaccinology: Beyond the Reflection of Infectious Responses Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma Tumor Microenvironment Remodeling by 4-Methylumbelliferone Boosts the Antitumor Effect of Combined Immunotherapy in Murine Colorectal Carcinoma.Gemcitabine enhances antitumor efficacy of recombinant lipoimmunogen-based immunotherapy.Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value.Colorectal clinical trials: what is on the horizon?Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine Actionable Intelligence Provided by Pancreatic Cancer Genomic Landscape: Are Targets for Curative Therapy On The Map?Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3(+)CD8(+) T cells against Various Solid Tumors.Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer Trial Watch: Immunotherapy plus radiation therapy for oncological indications.Role of immune cells in pancreatic cancer from bench to clinical application: An updated review Prognostic value of PDL1 expression in pancreatic cancer Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth.Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis.TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner.Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines.Seed-in-Soil: Pancreatic Cancer Influenced by Tumor Microenvironment.Immunotherapy of Prostate Cancer: Facts and Hopes.What treatment in 2017 for inoperable pancreatic cancers?

P2860

Q26744808-0102783D-1734-470B-85BB-12F566AA09D2 Q26747140-A6CF037F-2ADF-444A-A2FA-C44F9C5740D1 Q26749451-B355B49E-7956-4BA7-A1A1-C8FE16AEDDA6 Q26774641-D5AAAC46-E09D-433F-8933-1B1FD44191BB Q26777403-D70EE2C3-4C68-46D6-A9AF-53A4826C00D0 Q26778793-9BCEA90E-14B0-4291-929C-B5FE54B0371D Q26781215-CD879377-89C6-4435-96B5-0679390468D4 Q28066199-24CD2C77-3759-4369-A6D4-546480179F50 Q28069864-5FE4A9BC-1A0B-4F4F-B2A1-2FFBBEF10D86 Q28072532-848ABABB-5B62-4D82-8A10-B04DA5F61674 Q28076103-B2FCDD44-92DD-4FF0-BC6E-70839057ADB6 Q28078390-24919CD7-FEF0-4AB8-B4AD-0C4DA5E725F1 Q30846001-BEEF1B11-2D94-4AE6-9EA9-54D010AF70B1 Q33718737-BDC75DFD-4F48-4DF7-ACFF-A9C3BFD9E6D2 Q33728672-76497A07-EFDE-43CF-AE55-9B21ECE7C19A Q33779875-2926EEE1-BFA8-48A4-B031-6F75C79BE9EF Q35077467-B1ACE730-688D-4A19-BFBE-B699789A5FB0 Q36173622-3C402268-AB20-4127-B3E8-3F2EAFD18A38 Q36642440-F8369113-04BB-4020-9999-C19176B44E62 Q36661995-9EED4621-6BAA-4CCC-A7AD-9E6D3B2DA5C0 Q36757056-56FB4EAF-DBFD-4CA8-9B81-305F50A56CD1 Q36821133-668A79C8-C123-42EE-922D-5EFFB24AB864 Q36821149-F224EA21-AED9-4D28-A9D6-39CEF92C616D Q37029731-947C0872-0F77-4700-9E63-C418AC6A13C1 Q37135340-897218C5-5BB0-4065-A905-E1C7C58A5358 Q37157958-D7D29CCB-A840-4810-866F-ECF8EFE30A67 Q37230991-0D135A9F-9D2D-4B28-A30D-59FE7E008222 Q37265792-696360C1-BF08-49E6-847C-B5EF63CB043A Q37275289-5C7F2CD6-450D-4241-97E5-D329949AE692 Q37294755-A4A92C50-C6B1-4FA0-9EE1-B63B59F6C4E9 Q37308207-AAFC5A0C-DB2D-43B2-9C0C-C28337290236 Q37606102-6BEFC017-01C6-4CE6-B102-BE166CCD1913 Q37687595-8EAAE953-5452-4A71-98AA-F32DDA09E80F Q37689046-0E730792-035D-48EA-B9A5-0155573BCEF7 Q38375185-76111232-B57E-417F-9F22-24AA378C754E Q38632049-E4AFE3E6-8489-4E58-83A1-E578B89BCC55 Q38643567-4E92B721-0B3E-41D5-B1C6-913C19CCCE84 Q38650250-04F85C4E-4D5D-4590-BBE3-8526B0E66943 Q38664882-A7F81579-4092-4516-BD97-81FC48B7BDD2 Q38689025-00DD80EA-83FE-426F-AA59-FF9C2903F244

P2860

PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.

http://www.wikidata.org/entity/Q34644359

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

PD-1/PD-L1 blockade together w ...... ration into pancreatic tumors.

@ast

PD-1/PD-L1 blockade together w ...... ration into pancreatic tumors.

@en

PD-1/PD-L1 blockade together w ...... ration into pancreatic tumors.

@nl

type

label

PD-1/PD-L1 blockade together w ...... ration into pancreatic tumors.

@ast

PD-1/PD-L1 blockade together w ...... ration into pancreatic tumors.

@en

PD-1/PD-L1 blockade together w ...... ration into pancreatic tumors.

@nl

prefLabel

PD-1/PD-L1 blockade together w ...... ration into pancreatic tumors.

@ast

PD-1/PD-L1 blockade together w ...... ration into pancreatic tumors.

@en

PD-1/PD-L1 blockade together w ...... ration into pancreatic tumors.

@nl

P1433

Q34644359-F2451AE1-2048-461A-AD20-2A16E0767742

P1476

Q34644359-5331B072-D36E-449E-B635-88C52EC2CA80

P2093

Q34644359-1121BC2D-BC8D-4CCA-9353-A24843EE8D5B

Q34644359-22B06650-4304-490B-B654-5570B736CABF

Q34644359-262AF352-D126-4F04-9436-2C9AD1AFBCDC

Q34644359-37413F9C-CC4D-4141-AE8A-CAFC0619EFE2

Q34644359-401BA83B-5B9B-4AE3-8F1E-4DCA59A5ACFA

Q34644359-58D37D4D-8142-4CFD-81D4-B84215BE0F3C

Q34644359-6D05D67A-A932-4ACE-B009-9CF5D2C60728

Q34644359-78C19581-3C9C-4437-8B46-CC60967D18A8

Q34644359-7AE8DBDD-4BD2-4EBF-9C51-33B7172254D5

Q34644359-86BD3974-6926-4E23-B161-22753A9875EB

P2860

Q34644359-030F109E-1BA6-429C-98F3-F6F3763DC154

Q34644359-03B08DC6-E253-473C-9880-D37F820A0E3D

Q34644359-05841871-7C46-46E9-857C-2D4E27D05750

Q34644359-0FFCAA7C-A7BC-42F2-A362-29B2D7F84991

Q34644359-14E76918-349B-4581-9562-69252BBD51DF

Q34644359-1BDA97B5-E3AD-4C76-8F7B-9028BFF4CCC2

Q34644359-23280F5C-F4B0-4311-885D-35D37488522E

Q34644359-2AE591B8-C68C-44BC-9CF5-BA359415D1F5

Q34644359-2D48FE11-D8A9-4871-90C3-ECEA1AAE7456

Q34644359-2D83D324-6F0D-4598-8815-3CF680BD149B

P304

Q34644359-499E6057-CD23-4698-8222-04D5E6ED7019

P31

Q34644359-EA19AA62-A8C4-4B41-921E-CC7F582DBDE4

P356

Q34644359-F2A0CE63-2116-46DA-8764-A1E95BDBE9B7

P433

Q34644359-662CB1A5-DDCE-42F7-8B6F-A393DA25DF5F

P478

Q34644359-20AC0C9B-42D2-4A95-980D-394F72211BB7

P50

Q34644359-3FC4A99D-5BB6-4FA9-8523-262E6B5FD359

Q34644359-B1D2AB8B-9D29-4B2A-8B2F-C89D98844888

P577

Q34644359-ABE31FCF-08AB-46C1-B3FB-05076170D9FB

P698

Q34644359-4670966C-AC7F-447E-8F48-2B13C9A31B2B

P932

Q34644359-6B4AAE0D-861D-4967-95AA-FBB0FDB33238

P356

CJI.0000000000000062

P1433

Journal of Immunotherapy

P1476

PD-1/PD-L1 blockade together w ...... ration into pancreatic tumors.

@en

P2093

Agnieszka A Rucki

http://www.w3.org/2001/XMLSchema#string

Anthony Wamwea

http://www.w3.org/2001/XMLSchema#string

Barish H Edil

http://www.w3.org/2001/XMLSchema#string

Christopher L Wolfgang

http://www.w3.org/2001/XMLSchema#string

Daniel Laheru

http://www.w3.org/2001/XMLSchema#string

Elaine Bigelow

http://www.w3.org/2001/XMLSchema#string

Elizabeth M Jaffee

http://www.w3.org/2001/XMLSchema#string

Eric Lutz

http://www.w3.org/2001/XMLSchema#string

Kevin C Soares

http://www.w3.org/2001/XMLSchema#string

Lei Zheng

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

The PD-1 pathway in tolerance and autoimmunity

Inflammatory networks and immune surveillance of pancreatic carcinoma

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

PD-1 and its ligands in tolerance and immunity

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

P304

1-11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/CJI.0000000000000062

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25415283

http://www.w3.org/2001/XMLSchema#string

P932

4258151

http://www.w3.org/2001/XMLSchema#string